Publication | Closed Access
The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
24
Citations
0
References
2017
Year
Lymphoma CasesImmunodeficienciesImmunologyPathologyImmunotherapyTumor BiologyMyeloid NeoplasiaHematological MalignancyOncologyHematologyCancer Cell BiologyRadiation OncologyMolecular OncologyCancer ResearchHealth SciencesLymphoid NeoplasiaPrognostic RoleImmune SurveillanceNegative ExpressionTumor MicroenvironmentDlbcl PatientsMalignant Blood DisorderAdult T-cell Leukemia-lymphomaMedicine
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of lymphoid malignancies, which counts for more than a third of non-Hodgkin's lymphoma cases. The aim of the current study is to evaluate the prognostic role of several immunohistochemical (IHC) markers involved in the pathological process of DLBCL. This is a retrospective analysis of the 97 de novo DLBCL patients admitted between January 2007 and December 2016 in the Department of Hematology, "Filantropia" Municipal Hospital, Craiova, Romania. The expression of Bcl-2, Ki67, c-MYC and p53 was assessed by immunohistochemistry. A significant level of association was observed between high prognostic index values and Bcl-2, Ki67, c-MYC and p53 positive cases. Moreover, overall survival and disease-free survival were higher in patients with negative expression for these markers. Bcl-2, Ki67, c-MYC and p53 could make important diagnostic and therapeutic targets; therefore, their routine assessment should be mandatory.